Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Europe’s CHMP Recommends Rituximab Biosimilar Approval

December 30, 2021

Europe's Committee for Medicinal Products for Human Use (CHMP) recommended approval for a biosimilar version of rituximab for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). If approved by the European Commission, the biosimilar rituximab would be available as a 500 mg concentrate solution for infusion.

The hematologic indications for biosimilar rituximab include:

  • NHL
    • In combination with chemotherapy for previously untreated patients with stage 3 or 4 follicular lymphoma (FL)
    • Maintenance therapy for patients with FL who have responded to induction therapy
    • Monotherapy for patients with stage 3 or 4 FL who are resistant to chemotherapy or have relapsed ≥2 times following chemotherapy
    • In combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) for patients with CD20-positive diffuse large B-cell NHL
  • CLL
    • In combination with chemotherapy for patients with previously untreated and relapsed/refractory CLL

The biosimilar rituximab also received support from CHMP for the treatment of non-rheumatoid arthritis and granulomatosis with polyangiitis and microscopic polyangiitis.

Source: European Medicines Agency news release, December 15, 2016.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals